Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo

Two clinical-stage anticancer drugs, the Bcl-2 inhibitor ABT-263, and the MDM2 inhibitor SAR405838 achieve complete tumor regression in animal models of leukemia but also induce acquired resistance. Elucidation of acquired resistance mechanisms and development of strategies to overcome the resistanc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2015-06, Vol.21 (11), p.2558-2568
Hauptverfasser:	Hoffman-Luca, C Gianna, Ziazadeh, Daniel, McEachern, Donna, Zhao, Yujun, Sun, Wei, Debussche, Laurent, Wang, Shaomeng
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Apoptosis - drug effects Biphenyl Compounds - administration & dosage Cell Line, Tumor Drug Resistance, Neoplasm - genetics Humans Indoles - administration & dosage Leukemia - drug therapy Leukemia - genetics Leukemia - pathology Mice Nitrophenols - administration & dosage Piperazines - administration & dosage Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors Proto-Oncogene Proteins c-bcl-2 - genetics Proto-Oncogene Proteins c-mdm2 - antagonists & inhibitors Proto-Oncogene Proteins c-mdm2 - genetics Spiro Compounds - administration & dosage Sulfonamides - administration & dosage Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!